Angiogenesis in Glioma
- 1 May 2003
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 9 (3) , 205-213
- https://doi.org/10.1097/00130404-200305000-00008
Abstract
Gliomas are characterized by very high levels of neo-vascularization holding out the hope that therapies aimed at angiogenesis will have a significant impact on this intractable family of tumors. Intense research into the molecular mechanisms that drive the formation of new blood vessels in response to tumor growth has revealed a great deal of complexity, at the heart of which are competing pro- and anti-angiogenic influences. The relevant signaling pathways, and how they might be manipulated to interfere in the promotion of vessel growth are discussed. Several types of anti-angiogenic lead compounds are already in clinical trials, but assessing their impact on brain tumors is not straightforward. We discuss in depth some of the practical aspects of using imaging to more meaningfully follow tumor progression and response to treatment, which is particularly relevant to the use of therapies that target blood flow directly, which is fundamental to modern imaging modalities.Keywords
This publication has 67 references indexed in Scilit:
- Genetic modulation of hypoxia induced gene expression and angiogenesis relevance to brain tumorsFrontiers in Bioscience-Landmark, 2003
- Glomeruloid Microvascular Proliferation Orchestrated by VPF/VEGFThe American Journal of Pathology, 2001
- Vascular-specific growth factors and blood vessel formationNature, 2000
- Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesisInternational Journal of Cancer, 1999
- Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)Proceedings of the National Academy of Sciences, 1998
- Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF 121 and VEGF 165 but not VEGF 189Proceedings of the National Academy of Sciences, 1997
- Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.Proceedings of the National Academy of Sciences, 1996
- Angiogenesis in malignant gliomasGlia, 1995
- Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivoNature, 1992
- Anti-AngiogenesisAnnals of Surgery, 1972